A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using (18)F-FES PET/CT imaging

BACKGROUND: Elacestrant is an oral selective estrogen receptor (ER) degrader. This phase 1b open-label, non-randomized study (RAD1901-106) was initiated to determine the effect of elacestrant on the availability of ER in lesions from postmenopausal women with ER+ advanced breast cancer (ABC) using 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Jager, Agnes, de Vries, Elisabeth G. E., der Houven van Oordt, C. Willemien Menke-van, Neven, Patrick, Venema, Clasina M., Glaudemans, Andor W. J. M., Wang, Yamei, Bagley, Rebecca G., Conlan, Maureen G., Aftimos, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488419/
https://www.ncbi.nlm.nih.gov/pubmed/32912274
http://dx.doi.org/10.1186/s13058-020-01333-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488419/
https://www.ncbi.nlm.nih.gov/pubmed/32912274
http://dx.doi.org/10.1186/s13058-020-01333-3

Ejemplares similares